Contemporary Immunomodulatory Therapy for Multiple Sclerosis

Update item information
Title Journal of Neuro-Ophthalmology, December 2001, Volume 21, Issue 4
Publisher Lippincott, Williams & Wilkins
Date 2001-12
Type Text
Language eng
Rights Management © North American Neuro-Ophthalmology Society
Publication Type Journal Article
ARK ark:/87278/s6md254v
Setname ehsl_novel_jno
Date Created 2008-10-25
Date Modified 2020-03-03
ID 225101
Reference URL

Page Metadata

Title Contemporary Immunomodulatory Therapy for Multiple Sclerosis
Creator Rudick, RA
Affiliation Department of Neurology, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
Subject Adjuvants, Immunologic/therapeutic use; Humans; Interferon-beta/therapeutic use; Multiple Sclerosis/drug therapy; Recurrence
Abstract Multiple sclerosis (MS) is no longer considered an unmanageable disease. Five drugs have obtained regulatory approval to safely and effectively modify the course of MS. Three preparations of interferon beta-Avonex (interferon beta-1a), Betaseron (interferon beta-1b), and Rebif (interferon beta 1a)-have shown efficacy in relapsing-remitting MS and show promise in slowing the course of secondary progressive MS. Glatiramir acetate (Copaxone) has demonstrated efficacy in relapsing-remitting MS, and is being tested for the management of primary progressive disease. Mitoxantrone (Novantrone) has been approved for secondary progressive and progressive relapsing MS. There is a tendency toward early diagnosis and treatment based on the hypothesis that treatment effectiveness declines with advancing disease.
OCR Text Show
Setname ehsl_novel_jno
Date Created 2008-10-25
Date Modified 2021-05-06
ID 225090
Reference URL